Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
NCT01904773
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Tourette Syndrome
Interventions
DRUG:
AZD5213 and placebo
Sponsor
AstraZeneca